CompletedEUCTR 2010-022257-41
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Finland · Germany and 2 more locations
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 615
- Sponsor
- Takeda Global Research and Development Centre (Europe) Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Finland, Germany, Latvia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2010-022257-41
- Official title
Show the full official title
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedFinland · Germany · Latvia
1 more locations
- Romania
Questions about this study
Who is behind this study?
The study sponsor is Takeda Global Research and Development Centre (Europe) Ltd.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
§ Procaine Periarticular Injections for Pain Reduction in Elderly With Osteoarthritis
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide